Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment

Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment

Sponsors

Lead Sponsor: Asociación para Evitar la Ceguera en México

Source Asociación para Evitar la Ceguera en México
Brief Summary

To investigate the feasibility and advantages of using pressurized perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting 23 GA vitrectomy using a dual, dynamic drive (3D)technology, in complicated retinal detachment surgeries.

Overall Status Unknown status
Start Date March 2007
Completion Date February 2008
Phase Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Perfluorocarbon liquids consumption two months
Enrollment 10
Condition
Intervention

Intervention Type: Procedure

Intervention Name: Vitrectomy

Description: pressurized 23GA vitrectomy with a 3D system

Eligibility

Criteria:

Inclusion Criteria:

- Complicated retinal detachment with no more than 6months of evolution

Exclusion Criteria:

- Retinal detachments of more than 6 months of evolution No light perception

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Overall Contact

Last Name: Hugo Quiroz-Mercado, MD

Phone: 5255 10841400

Phone Ext.: 1171

Email: [email protected]

Location
Facility: Status: Contact: Investigator: Asociación para Evitar la Ceguera en México, Hospital "Luis Sánchez Bulnes" Hugo Quiroz-Mercado, MD 5255 10841400 1171 [email protected] Maria A Martinez-Castellanos, MD Sub-Investigator Gerardo Garcia-Aguirre, MD Sub-Investigator Orlando Ustariz-Gonzalez, MD Sub-Investigator Jose L Guerrero-Naranjo, MD Sub-Investigator Jans Fromow-Guerra, MD Sub-Investigator
Location Countries

Mexico

Verification Date

November 2007

Responsible Party

Name Title: Hugo Quiroz-Mercado

Organization: Asociacion para evitar la ceguera en Mexico

Has Expanded Access No
Condition Browse
Study Design Info

Allocation: Non-Randomized

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov